Notice regarding the recording of corporate tax adjustments (profit) (pdf, 91KB)
Notice regarding the recording of corporate tax adjustments (profit) (pdf, 91KB)
Nippon Chemifa Co., Ltd.
日本ケミファ株式会社Nippon Chemiphar Co., Ltd.AliasNippon Chemifa CorporationAliasChemipharm Co., Ltd.Alias
§01
Basic information
- Head office
- Not disclosed
- Chief executive
- Not disclosed
- Capital
- 4,304,000,000 (43 100 million)
- Employees (non-consolidated)
- 330 people
- Employees (consolidated)
- 878 people
- Start date
- 1947-07-01
- End date
§02
Websites
§03
Business
Manufacturing and sales of pharmaceutical drugs for medical useManufacturing and sales of clinical diagnostic reagentsImport and export businessManufacturing and sales of pharmaceuticalsProvision of healthcare productsDevelopment, manufacturing, and sales of generic pharmaceuticalsDevelopment and sales of clinical diagnostic reagentsResearch and development of new drugsSales of healthcare productsResearch and development
§04
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
| ジャパンソファルシム株式会社 |
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
Drag to move · click to open
§06
History
Commenced sales of pharmaceutical drugs for medical use
Established Hitachi Chemical Co., Ltd. (formerly) and began sales of medical pharmaceuticals.
Nippon Chemifa Co., Ltd. was founded in 1950.
Opened a factory in Hatanaka, Shibuya-ku, Tokyo
Introduced 'Timpanol' from Italy for the first time, began overseas transactions, relocated headquarters to Bunkyo-ku, Tokyo
Introduced 'Timpanoor' from Italy for the first time, commenced overseas transactions, and moved headquarters to Bunkyo-ku, Tokyo.
Opened a grass processing plant in Misato City, Saitama Prefecture
Made Nippon Pharmaceutical Industry Co., Ltd. a related company (currently a consolidated subsidiary)
Changed company name to Nippon Chemifa Co., Ltd.
Listed shares on the Second Section of the Tokyo Stock Exchange
Established a research laboratory within the grass processing plant
Relocated headquarters to Chiyoda-ku, Tokyo (current location)
Reclassified to the First Section of the Tokyo Stock Exchange, entered the clinical diagnostic reagent business, established Japan Sofar Sim Co., Ltd. (currently a related company)
Reclassified to the First Section of the Tokyo Stock Exchange: entered the clinical diagnostic reagent business: established Japan Sofarshim Co., Ltd. (currently a subsidiary).
Opened the Ibaraki factory (now Japan Pharmaceutical Industry Tsukuba Factory) in Maki District, Ibaraki Prefecture (now Chikusei City).
Established Shapuro Co., Ltd. (currently dormant), entering the cosmetics and health food sectors.
Made the Compound Safety Research Institute Co., Ltd. a subsidiary (now a consolidated subsidiary).
Released the alkali chemotherapy agent 'Uralit-U'.
Released the alkali chemotherapy agent 'Uralit-U'.
Released 'Uralit tablets'.
Released 'Uralit tablets'.
Released the analgesic and anti-inflammatory 'Soretone tablets'.
Released the hypertension treatment 'Carban tablets'.
Fully entered the generic pharmaceutical business.
Since 2000, generic pharmaceuticals have been positioned as the core of the business, and development, manufacturing, and sales are consistently handled within the group.
Released the allergy-specific IgE measurement device 'DiaPack2000' and dedicated measurement reagent 'Oriton IgE: Chemifa'.
Commenced a comprehensive business partnership with Ranbaxy Laboratories Limited (headquartered in India).
Commenced a capital and business partnership with Nippon Pharmacy Co., Ltd.
Introduced the lipid metabolism improvement agent 'NC-2400' to Cerenis, and merged Japan Pharmaceutical Industry Co., Ltd. into a 50:50 joint company with Ranbaxy.
Derived the lipid metabolism improvement agent 'NC-2400' to Cerenis, and merged Nippon Yakuhin Kogyo Co., Ltd. with Ranbaxy into a 50:50 joint company.
Ended the comprehensive business partnership with Ranbaxy, repurchased 50% of Japan Pharmaceutical Industry Co., Ltd.'s shares, and converted the joint venture into a subsidiary.
Ended comprehensive business partnership with Ranbaxy: repurchased 50% of Nippon Yakuhin Kogyo Co., Ltd.'s shares and made the joint venture a subsidiary.
Made Japan Pharmaceutical Industry Co., Ltd. a 100% subsidiary, absorbed the Ibaraki factory into Japan Pharmaceutical Industry Co., Ltd., and ended the business partnership with Nippon Pharmacy Co., Ltd.
Made Nippon Yakuhin Kogyo Co., Ltd. a 100% subsidiary, absorbed the Ibaraki plant into Nippon Yakuhin Kogyo Co., Ltd., and ended the business partnership with Nihon Chouzai Co., Ltd.
Released the allergy-specific IgE measurement device 'DiaPack3000'.
Completed Building 3 of the Japan Pharmaceutical Industry Co., Ltd. Tsukuba Factory.
Established Nippon Chemiphar Vietnam Co., Ltd. (NC-VN) in Vietnam.
NC-VN completed a manufacturing plant in Binh Son Province, Vietnam, and opened a West Japan logistics center in Kobe, Hyogo Prefecture, establishing a two-base system.
NC-VN completed a manufacturing plant in Binh Son Province, Vietnam, and opened a West Japan logistics center in Kobe City, Hyogo Prefecture, establishing a two-site system in the east and west.
NC-VN Vietnam factory began exporting to Japan.
Acquired the oral intestinal lavage agent 'PicoPrep combination oral formulation' from Feling Pharma Co., Ltd.
Launch of allergy screening equipment and reagents 'Drop Screen', signed a license agreement with Delta-Fly Pharma Inc. regarding the cancer microenvironment improvement agent 'DFP-17729', transferred sales of the macrolide antibiotic formulation 'Clarithid' from Mylan EPD LLC, and commenced patient enrollment for Phase I and II trials of the cancer microenvironment improvement agent 'DFP-17729'.
Launch of allergy screening equipment and reagents 'Drop Screen', signed a license agreement with Delta-Fly Pharma Inc. regarding the cancer microenvironment improvement agent 'DFP-17729', transferred sales of the macrolide antibiotic formulation 'Clarithid' from Mylan EPD LLC, and commenced patient enrollment for Phase I and II trials of the cancer microenvironment improvement agent 'DFP-17729'.
Transitioned to Phase II trial of the cancer microenvironment improvement agent 'DFP-17729', entered into a joint research and development agreement and option contract with Daiichi Sankyo Co., Ltd. regarding the opioid delta receptor agonist 'NC-2800', and began Phase I in July.
Transitioned to Phase II trial of the cancer microenvironment improvement agent 'DFP-17729', entered into a joint research and development agreement and option contract with Daiichi Sankyo Co., Ltd. regarding the opioid delta receptor agonist 'NC-2800', and began Phase I in July.
Signed a license agreement with Delta-Fly Pharma Inc. regarding the anticancer candidate compound 'DFP-14323'.
Entered into a license agreement with a Chinese company for the XOR inhibitor 'NC-2500', and signed a sales agreement with Fujifilm Medical Corporation regarding 'Drop Screen'.
Entered into a license agreement with a Chinese company for the XOR inhibitor 'NC-2500', and signed a sales agreement with Fujifilm Medical Corporation regarding 'Drop Screen'.
Launched the authorized generic (AG) 'Glimepiride tablets "NC"' of the sulfonylurea oral hypoglycemic agent Amaryl® tablets manufactured and sold by Sanofi, and commenced patient enrollment for Phase II and III trials of the cancer microenvironment improvement agent 'DFP-17729'.
Launched the authorized generic (AG) 'Glimepiride tablets "NC"' of the sulfonylurea oral hypoglycemic agent Amaryl® tablets manufactured and sold by Sanofi, and commenced patient enrollment for Phase II and III trials of the cancer microenvironment improvement agent 'DFP-17729'.
§07
News
Notice regarding the recording of corporate tax adjustments (profit) (pdf, 91KB)
Rakuten Ichiba 'Kemifa Shop' Opening and Commemorative Campaign
Japan Kemifa aims to expand sales of healthcare products and will grand-open the 'Kemifa Shop' on Rakuten Ichiba on October 23, 2026. The opening commemorative campaign is scheduled to run from October 23 to November 23. The shop will carry a total of 14 items, including quasi-drugs, cosmetics, health foods, and miscellaneous goods.
Transfer of Marketing Authorization for Expectorant Mucosolvan
Nippon Chemiphar Co., Ltd. announced the transfer of the marketing authorization for the expectorant Mucosolvan. The announcement was made as part of its investor relations disclosures.
Insurance Coverage and Launch of New Reagent for Allergy Testing Device "Drop Screen"
Nichi-Iko Chemifa announced that insurance coverage procedures have been completed for the new reagent for the allergy testing device and reagent "Drop Screen." Accordingly, the new product is also scheduled to be launched.
Personnel changes effective October 1, 2026
Nobutoshi Izawa will move from Deputy General Manager of the Distribution Relations Department in the Group Pharmaceutical Sales Headquarters to Tokyo Branch Manager. Keiichi Abekawa will move from Tokyo Branch Manager to Deputy General Manager of the Sales Planning and Promotion Department. Both changes take effect on October 1, 2026.
Nihon Chemiphar Obtains Manufacturing and Marketing Approval
Nihon Chemiphar announced that it obtained manufacturing and marketing approval on August 17, 2026. The information is intended for shareholders and investors, rather than the general public.
Nihon Chemiphar Completes Notifications and Certification for New Drop Screen Equipment and Reagent
Nihon Chemiphar completed the required notifications for new Drop Screen measurement equipment and a new reagent, and obtained certification. The additions are expected to expand the company's product lineup. See the PDF for details.
Support for the Kumamoto Earthquake Disaster
Japan Chemifa Co., Ltd. and Japan Pharmaceutical Industry Co., Ltd. donated 2 million yen in relief funds through the Japanese Red Cross Society to aid the relief of victims and the reconstruction of the disaster area.
Notice of personnel transfer of Japan Chemifa Corporation
Mr. Masashi Nishimura will assume the position of Director of Reliability Assurance General Department as of July 1, 2026.
Notice of the 94th Annual General Meeting of Shareholders
Notification regarding the resolutions of Japan Chemifa Corporation's 94th Annual General Meeting of Shareholders.
§08
Public records
National Tax Agency basic information5010001033101
Source: National Tax Agency Corporate Number Publication Site, basic three items
- Trade name
- 日本ケミファ株式会社
- Trade name (kana)
- ニッポンケミファ
- Name in English
- Corporation type
- 301
- Address
- 〒101-0032 東京都千代田区岩本町２丁目２番３号
- Postal code
- 1010032
- Prefecture code
- 13
- City code
- 101
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-07-17
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1866138
METI gBizINFO5010001033101
Source: gBizINFO (Ministry of Economy, Trade and Industry)
- Corporate number
- 5010001033101
- Trade name
- 日本ケミファ株式会社
- Trade name (kana)
- ニッポンケミファ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都千代田区岩本町２丁目２番３号
- Postal code
- 1010032
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 千代田区
- City code
- 101
- Street address
- 岩本町２丁目２番３号
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 山 口 一 城
- Capital
- 4304000000
- Employees
- 421
- Employees (male)
- 307
- Employees (female)
- 114
- Business summary
- 医療用医薬品・臨床検査薬の製造・販売および輸出入業 健康・医療関連事業
- Website URL
- http://www.chemiphar.co.jp/
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-07-17
- Key information
- 5010001033101
§09
Sources & updates
DOMAINOwn domain：Yes
UPDATED2026-09-29 14:26 · Model: gpt-4.1-nano